Companion Medical
Smart insulin pen cuts hypoglycemia by 93%
US
Companion Medical developed the InPen, a smart insulin pen system designed to simplify diabetes management. The company was acquired by Medtronic in 2020.
Problem Statement
Companion Medical aimed to simplify diabetes management for individuals using insulin pens by providing advanced delivery technology, real-time actionable insights, and improved communication with healthcare providers.
Core Technology
InPen smart insulin pen system
Key Differentiators
Developed a smart insulin pen system for advanced insulin delivery.; Provides real-time actionable insights for diabetes management.; Improves communication between patients and healthcare providers.
Clinical Focus
Diabetes
Company Info
- Business Model
- Hardware
- Total Funding
- 19,500,000
- Website
- www.companionmedical.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
FDA 510(k) cleared July 2016. Real-world evidence: 93% hypoglycemia reduction, 2-5% time-in-range improvement across 1,736 users (ADA 2021 presentation). Peer-reviewed validation in Diabetes Journal and JMCP.
MedStartr Index Score
?What do you think of Companion Medical?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.